Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
actinium-225-labeled titanium dioxide nanoparticles
- Development stage
- Preclinical
- Lead developer
- Charles University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Actinium-225-labeled titanium dioxide nanoparticles ([225Ac]TiO2) are radiolabeled metal oxide nanoparticles being investigated as potential carriers for targeted alpha therapy (TAT) in oncology. Titanium dioxide (TiO2) nanoparticles are utilized as a carrier matrix to stably retain the alpha-emitting radionuclide actinium-225 (225Ac) and its radioactive decay progeny (such as francium-221 and bismuth-213). This retention is critical to prevent the escape of daughter radionuclides (recoil effect) and minimize off-target toxicity to healthy tissues. The nanoparticles are prepared by hydrolysis of tetra-n-butyl orthotitanate and labeled with 225Ac via surface sorption or doping during synthesis. They are being evaluated in preclinical research for their stability, progeny retention, and biodistribution.
- Other names
- 225Ac-labeled TiO2 nanoparticles225Ac-labeled titanium dioxide nanoparticles225Ac@TiO2225Ac@TiO2 nanoparticles[225Ac]TiO2[225Ac]TiO2 nanoparticlesactinium-225-labeled TiO2 nanoparticlesactinium225-labeled TiO2 nanoparticlesactinium 225-labeled TiO2 nanoparticles
Beyond the preview
Go deeper on actinium-225-labeled titanium dioxide nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on actinium-225-labeled titanium dioxide nanoparticles.